Barclays
KYMR icon

Barclays’s Kymera Therapeutics KYMR Stock Holding History

Barclays’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,400
Closed -$1.49M – 5386
2024
Q3 		$1.49M Buy
+31,400
New +$1.39M ﹤0.01% 3091

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Barclays's KYMR Position: Q1 2026 in Review

Barclays reduced its Kymera Therapeutics (KYMR) stake by 90% in Q1 2026, selling an estimated $10M and leaving 14,247 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2654.

Barclays first reported a position in KYMR in Q1 2022 and has held it in 17 quarters since. The position peaked at $12.9M in Q1 2024. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Barclays held 14,247 shares of Kymera Therapeutics worth $1.19M as of Q1 2026.
  • Barclays sold 126,260 Kymera Therapeutics shares in Q1 2026, an estimated $10M.
  • Kymera Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2654 holding.
  • Barclays first reported a position in Kymera Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Kymera Therapeutics position peaked at $12.9M in Q1 2024.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.